Time filter

Source Type

Patent
Foundation For Biomedical Research And Innovation, Tokai University, Stemmed Inc. and Juntendo Educational Foundation | Date: 2015-08-05

Simplification of a preparation step of a cell population used for the treatment of ischemic diseases, and provision of a cell population that shows more effect by the treatment. A method of producing a cell population wherein a vascular endothelial progenitor cell and/or an anti-inflammatory macrophage are/is enriched, including cultivating a mononuclear cell derived from bone marrow, cord blood or peripheral blood in a serum-free medium containing stem cell factor, interleukin-6, FMS-like tyrosine kinase 3 ligand, thrombopoietin and vascular endothelial cell growth factor, and proliferating vascular endothelial progenitor cell from the cell; and a cell population obtained by the method, etc.


Patent
National Cerebral And Cardiovascular Center, Foundation For Biomedical Research And Innovation, Hyogo College of Medicine, Hokkaido University and Kaneka Corporation | Date: 2014-08-18

An object of the present invention is to provide a method for producing a mesenchymal stromal cell composition, comprising conveniently and aseptically separating high-purity amnion-derived MSCs by performing enzyme treatment only once. According to the present invention, the following are provided: a method for producing a mesenchymal stromal cell composition, comprising: performing enzyme treatment of an amnion with collagenase and thermolysis and/or dispase; and filtering the enzyme-treated amnion through a mesh; a method for producing a cryopreserved mesenchymal stromal cell composition; and a therapeutic agent comprising as an active ingredient the mesenchymal stromal cell composition for a disease selected from graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, liver cirrhosis, or radiation enteritis.


Patent
National Cerebral And Cardiovascular Center, Foundation For Biomedical Research And Innovation, Hyogo College of Medicine, Hokkaido University and Kaneka Corporation | Date: 2016-06-29

An object of the present invention is to provide a method for producing a mesenchymal stromal cell composition, comprising conveniently and aseptically separating high-purity amnion-derived MSCs by performing enzyme treatment only once. According to the present invention, the following are provided: a method for producing a mesenchymal stromal cell composition, comprising: performing enzyme treatment of an amnion with collagenase and thermolysin and/or dispase; and filtering the enzyme-treated amnion through a mesh; a method for producing a cryopreserved mesenchymal stromal cell composition; and a therapeutic agent comprising as an active ingredient the mesenchymal stromal cell composition for a disease selected from graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, liver cirrhosis, or radiation enteritis.


Patent
Foundation For Biomedical Research And Innovation | Date: 2015-04-22

Provided is a prophylactic and/or therapeutic drug for mild cognitive impairment, which can improve interstitial flow in cerebral blood vessel and the like to achieve sufficient clearance of harmful proteins accumulated in the brain. The prophylactic and/or therapeutic drug includes 6-[4-(1-cyclohexyl-1H-tetrazole-5-yl)butoxy]3,4-dihydrocarbostyril or a salt thereof as an active ingredient. The prophylactic and/or therapeutic drug can improve a flow of interstitial fluid around blood vessels in a drainage pathway to excrete harmful proteins. The prophylactic and/or therapeutic drug for mild cognitive impairment may take the form of a pharmaceutical product for oral administration, a liquid pharmaceutical product for oral administration, or an injectable preparation. The prophylactic and/or therapeutic drug for mild cognitive impairment can be used for the prevention and/or treatment of cerebral amyloid angiopathy, and can also be used for improvement of Lewy body disease, Downs syndrome, or macular degeneration.


Patent
Foundation For Biomedical Research And Innovation | Date: 2013-06-14

Provided is a prophylactic and/or therapeutic drug for mild cognitive impairment, which can improve interstitial flow in cerebral blood vessel and the like to achieve sufficient clearance of harmful proteins accumulated in the brain. The prophylactic and/or therapeutic drug includes 6-[4-(1-cyclohexyl-1H-tetrazole-5-yl)butoxy]3,4-dihydrocarbostyril or a salt thereof as an active ingredient. The prophylactic and/or therapeutic drug can improve a flow of interstitial fluid around blood vessels in a drainage pathway to excrete harmful proteins. The prophylactic and/or therapeutic drug for mild cognitive impairment may take the form of a pharmaceutical product for oral administration, a liquid pharmaceutical product for oral administration, or an injectable preparation. The prophylactic and/or therapeutic drug for mild cognitive impairment can be used for the prevention and/or treatment of cerebral amyloid angiopathy, and can also be used for improvement of Lewy body disease, Downs syndrome, or macular degeneration.


Patent
Foundation For Biomedical Research And Innovation | Date: 2012-07-04

The present invention relates to a therapeutic agent for liver-related diseases, comprising adipose tissue-derived multilineage progenitor cells; and others.


Patent
Foundation For Biomedical Research And Innovation | Date: 2014-03-25

The invention provides a method of removing or reducing undifferentiated cells from a differentiated cell population contaminated or having a risk of contamination with undifferentiated cells by contacting a pigment epithelium-derived factor with the differentiated cell population to induce apoptosis of the undifferentiated cells. The invention also provides an agent for cell transplantation therapy, containing a differentiated cell population substantially free of an undifferentiated cell, which is obtained by the method, as well as an agent for inducing apoptosis of an undifferentiated cell, containing a pigment epithelium-derived factor, and combined use of the aforementioned agent for cell transplantation therapy and the aforementioned agent for inducing apoptosis.


Provided are a culture method of a corneal endothelial cell having a low risk of infection, which enables mass culture at a low cost, a production method of a corneal endothelial cell sheet for transplantation, a culture kit of a corneal endothelial cell and the like. A culture method of a corneal endothelial cell including culturing a corneal endothelial cell in a culture medium containing an ascorbic acid derivative, and the like.


Patent
Foundation For Biomedical Research And Innovation | Date: 2016-02-03

Provided is a pluripotent stem cell-derived differentiated cell with a reduced tumor risk. A method of removing or reducing undifferentiated cells from a differentiated cell population contaminated or having a risk of contamination with undifferentiated cells, including contacting a pigment epithelium-derived factor with the differentiated cell population to induce apoptosis of the undifferentiated cells. An agent for cell transplantation therapy, containing a differentiated cell population substantially free of an undifferentiated cell, which is obtained by the method. An agent for inducing apoptosis of an undifferentiated cell, containing a pigment epithelium-derived factor. Combined use of the aforementioned agent for cell transplantation therapy and the aforementioned agent for inducing apoptosis.


Patent
Foundation For Biomedical Research And Innovation | Date: 2015-09-21

Provided is a prophylactic and/or therapeutic drug for mild cognitive impairment, which can improve interstitial flow in cerebral blood vessel and the like to achieve sufficient clearance of harmful proteins accumulated in the brain. The prophylactic and/or therapeutic drug includes 6-[4-(1-cyclohexyl-1H-tetrazole-5-yl)butoxy]3,4-dihydrocarbostyril or a salt thereof as an active ingredient. The prophylactic and/or therapeutic drug can improve a flow of interstitial fluid around blood vessels in a drainage pathway to excrete harmful proteins. The prophylactic and/or therapeutic drug for mild cognitive impairment may take the form of a pharmaceutical product for oral administration, a liquid pharmaceutical product for oral administration, or an injectable preparation. The prophylactic and/or therapeutic drug for mild cognitive impairment can be used for the prevention and/or treatment of cerebral amyloid angiopathy, and can also be used for improvement of Lewy body disease, Downs syndrome, or macular degeneration.

Loading Foundation for Biomedical Research and Innovation collaborators
Loading Foundation for Biomedical Research and Innovation collaborators